Startseite>>Titanium dioxide

Titanium dioxide (Synonyms: Titanium dioxide)

Katalog-Nr.GD23152

100 nm, Rutile type,  lipophilic

Products are for research use only. Not for human use. We do not sell to patients.

Titanium dioxide Chemische Struktur

Cas No.: 13463-67-7

Größe Preis Lagerbestand Menge
500g
25,00 $
Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products
Titanium(IV) oxide is a photosensitizer. Titanium(IV) oxide can be used as an excipient, such as glidant, coating agent, opacifier, coloring agent. Pharmaceutical excipients, or pharmaceutical auxiliaries, refer to other chemical substances used in the pharmaceutical process other than pharmaceutical ingredients. Pharmaceutical excipients generally refer to inactive ingredients in pharmaceutical preparations, which can improve the stability, solubility and processability of pharmaceutical preparations. Pharmaceutical excipients also affect the absorption, distribution, metabolism, and elimination (ADME) processes of co-administered drugs.

[1]. Augustynski J. Aspects of photo-electrochemical and surface behaviour of titanium (IV) oxide[M]//Solid Materials. Berlin, Heidelberg: Springer Berlin Heidelberg, 2005: 1-61.

[2]. Elder DP, et al. Pharmaceutical excipients - quality, regulatory and biopharmaceutical considerations. Eur J Pharm Sci. 2016 May 25;87:88-99. 

Bewertungen

Review for Titanium dioxide

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Titanium dioxide

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.